Split History
ETFs Holding EPRS »    EPRS Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
EPIRUS Biopharmaceuticals is a biopharmaceutical company engaged in developing, manufacturing, and commercializing biosimilar therapeutics (biosimilars). Co.'s primary product candidate is BOW015, a biosimilar version of Remicade®. Remicade is marketed by Johnson & Johnson, Merck Schering and Mitsubishi Tanabe for the treatment of various inflammatory diseases. Co.'s biosimilar product candidates also includes BOW050, a biosimilar version of Humira®, which is marketed by AbbVie and used to treat inflammatory diseases, and BOW070, a biosimilar version of Actemra®, which is marketed by Genentech/Roche and used to treat inflammatory diseases. BOW050 and BOW070 are in preclinical development. According to our EPRS split history records, EPRS has had 1 split.
EPRS split history picture
EPRS (EPRS) has 1 split in our EPRS split history database. The split for EPRS took place on July 16, 2014. This was a 1 for 10 reverse split, meaning for each 10 shares of EPRS owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.

When a company such as EPRS conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the EPRS split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into EPRS shares, starting with a $10,000 purchase of EPRS, presented on a split-history-adjusted basis factoring in the complete EPRS split history. EPRS split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 06/24/2011
End date: 08/03/2016
Start price/share: $24.20
End price/share: $0.14
Dividends collected/share: $0.00
Total return: -99.42%
Average Annual Total Return: -63.48%
Starting investment: $10,000.00
Ending investment: $57.85
Years: 5.12
Date Ratio
07/16/20141 for 10
EPRS is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

ESMC Split History
ESRX Split History
ETRM Split History
EVFM Split History
EVHC Split History
EW Split History
EXAC Split History
EYEG Split History
EYES Split History
FCSC Split History

Trisura Group Ltd. (TSU.CA)
BetaPro NASDAQ-100 2x Daily Bull ETF (HQU)
BetaPro S&P 500 2x Daily Bull ETF (HSU)
BetaPro S&P/TSX Capped Energy 2x Daily Bull ETF (HEU)
BetaPro S&P/TSX Capped Financials 2x Daily Bull ETF (HFU)
BetaPro S&P/TSX 60 2x Daily Bull ETF (HXU)
BetaPro Crude Oil Leveraged Daily Bull ETF (HOU)
Horizons Big Data & Hardware Index ETF (HBGD.U)
Horizons Big Data & Hardware Index ETF (HBGD)
Horizons NASDAQ-100 Index ETF (HXQ.U)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

EPRS Insider Buying

EPRS Split History | www.SplitHistory.com | Copyright © 2013 - 2021, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.